SCHEMBL13429367

SCHEMBL13429367

CC(C)(C)OC(=O)Nc1ccc(CNc2cccc(Oc3cc(=O)[nH]c4ccccc34)c2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.43
NAMPT P43490 1/20 0.40
AURKA O14965 2/20 0.38
RPS6KB1 P23443 2/20 0.38
BRAF P15056 8/20 0.38
SCN9A Q15858 1/20 0.37
RAF1 P04049 1/20 0.37
LCK P06239 1/20 0.37
RET P07949 1/20 0.37
PDGFRB P09619 1/20 0.37
KIT P10721 1/20 0.37
PDGFRA P16234 1/20 0.37
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK14 Q16539 1/20 0.37
MAPK8 P45983 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429372 0.87 MEN1 (0.39) HDAC1BRAFRAF1LCKRET
SCHEMBL3221532 0.82 GAA (0.41) BRAFMAPK8MEN1KMT2AGAA
SCHEMBL13429319 0.81 MEN1 (0.45) HDAC1MEN1KMT2AGAAGABRA1
SCHEMBL13429368 0.80 MEN1 (0.42) BRAFMEN1KMT2AGAA
SCHEMBL3227033 0.80 MEN1 (0.40) BRAFMEN1KMT2AGAA
SCHEMBL13429362 0.80 CACNA1B (0.41) BRAFMAPK8MEN1KMT2AGAA
SCHEMBL13429357 0.79 AKT1 (0.37) BRAFRAF1LCKRETPDGFRB
SCHEMBL3219003 0.77 BRAF (0.48) BRAFMEN1KMT2AGAA
SCHEMBL3214639 0.77 SMN1; SMN2 (0.49) NAMPTBRAFMEN1KMT2AGAA
SCHEMBL13428990 0.76 P2RX7 (0.40) BRAFRAF1LCKRETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA HDAC1 416/4885NAMPT 1479/4885AURKA 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.